<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31307190</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>06</Day></DateCompleted><DateRevised><Year>2020</Year><Month>07</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2373-8227</ISSN><JournalIssue CitedMedium="Internet"><Volume>5</Volume><Issue>10</Issue><PubDate><Year>2019</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>ACS infectious diseases</Title><ISOAbbreviation>ACS Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Efficient Blocking of Enterovirus 71 Infection by Heparan Sulfate Analogues Acting as Decoy Receptors.</ArticleTitle><Pagination><StartPage>1708</StartPage><EndPage>1717</EndPage><MedlinePgn>1708-1717</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acsinfecdis.9b00070</ELocationID><Abstract><AbstractText>Enterovirus 71 (EV71) is a major etiological agent of hand, foot, and mouth disease, for which there is no antiviral therapy. We have developed densely sulfated disaccharide heparan sulfate (HS) analogues that are potent small molecule inhibitors of EV71 infection, binding to the viral capsid and acting as decoy receptors to block early events of virus replication. The simplified structures, more potent than defined HS disaccharides and with no significant anticoagulant activity, offer promise as anti-EV71 agents.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Earley</LastName><ForeName>Daniel F</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Institute for Glycomics , Griffith University , Gold Coast , Queensland 4222 , Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bailly</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Institute for Glycomics , Griffith University , Gold Coast , Queensland 4222 , Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maggioni</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Glycomics , Griffith University , Gold Coast , Queensland 4222 , Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kundur</LastName><ForeName>Avinash R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>School of Medical Science, Menzies Health Institute Queensland , Griffith University , Gold Coast , Queensland 4222 , Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thomson</LastName><ForeName>Robin J</ForeName><Initials>RJ</Initials><Identifier Source="ORCID">0000-0002-1014-2614</Identifier><AffiliationInfo><Affiliation>Institute for Glycomics , Griffith University , Gold Coast , Queensland 4222 , Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Chih-Wei</ForeName><Initials>CW</Initials><AffiliationInfo><Affiliation>Institute for Glycomics , Griffith University , Gold Coast , Queensland 4222 , Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>von Itzstein</LastName><ForeName>Mark</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6302-7524</Identifier><AffiliationInfo><Affiliation>Institute for Glycomics , Griffith University , Gold Coast , Queensland 4222 , Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>ACS Infect Dis</MedlineTA><NlmUniqueID>101654580</NlmUniqueID><ISSNLinking>2373-8227</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013002">Somatomedins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9050-30-0</RegistryNumber><NameOfSubstance UI="D006497">Heparitin Sulfate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="N">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006497" MajorTopicYN="N">Heparitin Sulfate</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013002" MajorTopicYN="N">Somatomedins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053585" MajorTopicYN="N">Virus Attachment</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HS analogue</Keyword><Keyword MajorTopicYN="N">binding inhibitor</Keyword><Keyword MajorTopicYN="N">enterovirus 71(EV71)</Keyword><Keyword MajorTopicYN="N">hand, foot, and mouth disease (HFMD)</Keyword><Keyword MajorTopicYN="N">heparan sulfate</Keyword><Keyword MajorTopicYN="N">sulfation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31307190</ArticleId><ArticleId IdType="doi">10.1021/acsinfecdis.9b00070</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>